ClinicalTrials.gg
TerminatedNCT01480453Updated Mar 26, 2019

Outcomes Study of the TM Humeral Stem Used in Primary, Total or Hemi Shoulder Arthroplasty

An observational study in Osteoarthritis, Rheumatoid Arthritis and Post-traumatic Arthritis, sponsored by Zimmer Biomet. Terminated at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-03-26.

Sponsored by Zimmer Biomet · Observational

Why this study was terminated
Business decision was made to remove the CE mark from this product, thus prompting the closing of this study.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
67
Ages
18 Years and older
Sex
All
01

Study summary

The objectives of this study are to obtain survival and outcome data on the Trabecular Metal Humeral Stem when used in primary, total or hemi shoulder arthroplasty.

Read the detailed description

The objectives of this study are to obtain survival and outcome data on the Trabecular Metal Humeral Stem when used in primary, total or hemi shoulder arthroplasty. This will be done by analysis of standard scoring systems, radiographs and adverse event records. Data will be collected and analyzed to monitor pain, function, and survivorship and to confirm the performance of the Trabecular Metal Humeral Stem.

Performance will be evaluated by monitoring the frequency and incidence of adverse events as well as by assessment of the overall pain and functional performances, survivorship, health status and radiographic parameters of all enrolled study subjects who receive the Trabecular Metal Humeral Stem.

Pain and functional performance will be measured using the American Shoulder and Elbow Surgeons (ASES) Shoulder Assessment and the Single Assessment Numeric Evaluation (SANE), survivorship will be based on removal or intended removal of the device, health status will be determined by evaluation of the SF-12 as well as AEs and radiographic parameters by analysis of x-rays.

02

Conditions studied

  • Osteoarthritis
  • Rheumatoid Arthritis
  • Post-traumatic Arthritis
  • Ununited Humeral Head Fracture
  • Irreducible 3- and 4-part Proximal Humeral Fractures
  • Avascular Necrosis

Keywords

  • Osteoarthritis
  • Rheumatoid arthritis
  • Post-traumatic arthritis
  • Ununited humeral head fracture
  • Irreducible 3- and 4-part proximal humeral fractures
  • Avascular necrosis
03

In context

Osteoarthritis

4,445 studies on the registry are indexed under Osteoarthritis; 582 are open to participants now.

This study's enrollment of 67 is below the median of 100 across 803 observational studies indexed under Osteoarthritis.

Browse Osteoarthritis studies →

Lead sponsor

Zimmer Biomet is the lead sponsor of 275 studies on the registry; 28 are open to participants now.

Of its 22 completed or terminated interventional studies of FDA-regulated products, 19 (86%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Each investigator will screen from his/her patients who suffer from Osteoarthritis, Rheumatoid arthritis, Post-traumatic arthritis, Ununited humeral head fracture, Irreducible 3- and 4-part proximal humeral fractures, Avascular necrosis who meet the inclusion/exclusion criteria stated in the protocol.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient is >18 years of age;
  • Patient is skeletally mature;
  • Patient qualifies for primary unilateral or bilateral total or hemi shoulder arthroplasty based on physical exam and medical history including the following: Osteoarthritis, Rheumatoid arthritis, Post-traumatic arthritis, Ununited humeral head fracture, Irreducible 3- and 4-part proximal humeral fractures, Avascular necrosis
  • Patient is willing and able to provide written informed consent;
  • Patient is willing and able to cooperate in the required post-operative therapy;
  • Patient is will and able to complete scheduled follow-up evaluations/questionnaires as described in the Informed Consent;
  • Patient has participated in the Informed Consent process and has signed the IRB/ERB approved informed consent;

Exclusion criteria

Exclusion Criteria:

  • The patient is a prisoner;
  • The patient is mentally incompetent or unable to understand what participation in the study entails;
  • The patient is a known alcohol or drug abuser;
  • The patient is anticipated to be non-compliant;
  • The patient has one of the following compromising the affected limb; a significant injury to the upper brachial plexus, paralysis of the axillary nerve or a neuromuscular disease compromising the affected limb which would render the procedure unjustifiable;
  • The patient has a local/systemic infection;
  • The patient is known to be pregnant;
  • The patient has marked bone loss;
  • The patient has a known sensitivity or allergic reaction to one or more of the implanted materials;
  • The patient is unwilling or unable to give consent or to comply with the follow-up program.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
67 participants (actual)

Groups and cohorts

  • Trabecular Metal Humeral Stem

    Patients requiring primary, total or hemi shoulder arthroplasty who receive the Trabecular Metal Humeral Stem.

    Device: Trabecular Metal Humeral Stem

Interventions

  • DeviceTrabecular Metal Humeral Stem

    Trabecular Metal Humeral Stem used in primary, total or hemi shoulder arthroplasty

    Also known as: TM Humeral Stem, TM Humeral

06

What researchers measure

Primary outcomes

  1. Survivorship

    Based on removal or intended removal of the device and determined using the Kaplan-Meier method.

    Time frame: 10 Years

Secondary outcomes

  1. Pain and Functional Performance

    Measurements will be based on the American Shoulder and Elbow Surgeons (ASES) Shoulder Assessment and the Single Assessment Numeric Evaluation (SANE)

    Time frame: 10 Years

07

Study locations

3 sites
  • Norton Orthopaedic Specialists
    Louisville, Kentucky 40241, United States
  • William Beaumont Hospital
    Royal Oak, Michigan 48073, United States
  • The Rothman Institute
    Philadelphia, Pennsylvania 19107, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 26, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01480453
Lead sponsor
Zimmer Biomet
Responsible party
Sponsor
First posted
Nov 28, 2011
Start date
Jan 2, 2011
Primary completion
Dec 31, 2018
Completion
Dec 31, 2018
Last update
Mar 26, 2019

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion